Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL

Core Points - Illumina, Inc. has filed a Form 10 registration statement with the SEC for the intended divestiture of GRAIL, which includes detailed financial and business information about GRAIL [1][4] - The divestiture plan has been approved by the European Commission, and Illumina aims to finalize the terms by the end of Q2 2024 [2][4] - GRAIL will host a virtual Capital Markets Day on May 13, 2024, to present its multi-cancer early detection test, Galleri, and discuss its business strategy and market opportunities [3] Company Overview - Illumina is a leader in DNA sequencing and array-based technologies, focusing on improving human health through innovation in various markets including life sciences and oncology [5] - GRAIL is dedicated to early cancer detection using advanced technologies such as next-generation sequencing and machine learning, aiming to alleviate the global burden of cancer [6] Transaction Details - The planned capital markets separation is intended to qualify as a tax-free distribution for U.S. shareholders, with a favorable IRS ruling received [4] - The divestiture is subject to conditions including final approval from Illumina's Board of Directors and the effectiveness of the Form 10 registration statement [4]